{"id":72433,"date":"2026-08-13T12:01:20","date_gmt":"2026-08-13T04:01:20","guid":{"rendered":"https:\/\/flcube.com\/?p=72433"},"modified":"2026-08-13T12:01:21","modified_gmt":"2026-08-13T04:01:21","slug":"zhaoke-ophthalmology-signs-exclusive-distribution-and-promotion-agreement-with-pengpai-bio-for-epinastine-hydrochloride-eye-drops-in-mainland-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=72433","title":{"rendered":"Zhaoke Ophthalmology Signs Exclusive Distribution and Promotion Agreement With Pengpai Bio for Epinastine Hydrochloride Eye Drops in Mainland China"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Zhaoke Ophthalmology<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/6622:HKG\">HKG: 6622<\/a>) announced that it has entered into an <strong>exclusive distribution and promotion agreement<\/strong> with <strong>Pengpai Bio<\/strong> for <strong>Epinastine Hydrochloride Eye Drops<\/strong>, covering <strong>all sales channels in Mainland China<\/strong> (excluding Hong Kong, Macao, and Taiwan) \u2014 a move designed to accelerate the commercial rollout of its newly approved ophthalmic generic across the country.<\/p>\n\n\n\n<h2 id=\"h-deal-milestone\" class=\"wp-block-heading\">Deal Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Parties<\/strong><\/td><td>Zhaoke Ophthalmology (HKG: 6622) \u00d7 Pengpai Bio<\/td><\/tr><tr><td><strong>Agreement Type<\/strong><\/td><td>Exclusive distribution and promotion agreement<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Epinastine Hydrochloride Eye Drops<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Mainland China \u2014 all sales channels (excluding HK, Macao, Taiwan)<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>12 Aug 2026<\/td><\/tr><tr><td><strong>NMPA Approval<\/strong><\/td><td>19 Nov 2025<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Treatment of symptoms associated with seasonal allergic conjunctivitis<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-product-profile-epinastine-hydrochloride-eye-drops\" class=\"wp-block-heading\">Product Profile \u2013 Epinastine Hydrochloride Eye Drops<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Origin:<\/strong> Epinastine was originally developed by <strong>Allergan<\/strong> under the brand name <strong>Elestat<\/strong>, first approved for marketing in the <strong>European Union in 2003<\/strong><\/li>\n\n\n\n<li><strong>Development:<\/strong> The approved product is a <strong>generic drug independently developed by Zhaoke Ophthalmology<\/strong>, cleared by the <strong>NMPA on 19 Nov 2025<\/strong><\/li>\n\n\n\n<li><strong>Rapid Onset:<\/strong> Validated by the <strong>Conjunctival Allergen Challenge (CAC) model<\/strong>, the product demonstrates onset of action <strong>within 3 minutes<\/strong> post-administration<\/li>\n\n\n\n<li><strong>Durable Effect:<\/strong> Therapeutic effects lasting for <strong>at least 8 hours<\/strong>, supporting convenient twice-daily or less frequent dosing<\/li>\n\n\n\n<li><strong>Safety:<\/strong> A favorable overall safety and tolerability profile<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Channel Coverage:<\/strong> The exclusive structure covering <strong>all Mainland China sales channels<\/strong> concentrates execution with Pengpai Bio, spanning hospitals, retail pharmacies, and online platforms \u2014 critical reach for an allergy-season-driven product.<\/li>\n\n\n\n<li><strong>Seasonal Demand Driver:<\/strong> Seasonal allergic conjunctivitis affects a large patient population in China, with demand peaking in spring and autumn allergy seasons, giving the product a recurring commercial catalyst.<\/li>\n\n\n\n<li><strong>Proven Molecule:<\/strong> Epinastine&#8217;s two-decade global clinical heritage under Elestat lowers prescriber and patient adoption barriers versus novel agents.<\/li>\n\n\n\n<li><strong>Zhaoke&#8217;s Portfolio Strategy:<\/strong> The partnership converts Zhaoke&#8217;s November NMPA approval into commercial scale without building an in-house sales force for the channel, preserving capital for its pipeline.<\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> Financial terms, including distribution targets and revenue-sharing provisions, were not disclosed.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding the commercialization of Epinastine Hydrochloride Eye Drops in Mainland China. Actual results may differ due to risks including market adoption, pricing and competitive dynamics in ophthalmic allergy treatments, and channel execution.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Zhaoke Ophthalmology (HKG: 6622) announced that it has entered into an exclusive distribution and promotion&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[942,44,4894,166],"class_list":["post-72433","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-hkg-6622","tag-ophthalmology","tag-pengpai-bio","tag-zhaoke-ophthalmology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Zhaoke Ophthalmology Signs Exclusive Distribution and Promotion Agreement With Pengpai Bio for Epinastine Hydrochloride Eye Drops in Mainland China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Zhaoke Ophthalmology (HKG: 6622) announced that it has entered into an exclusive distribution and promotion agreement with Pengpai Bio for Epinastine Hydrochloride Eye Drops, covering all sales channels in Mainland China (excluding Hong Kong, Macao, and Taiwan) \u2014 a move designed to accelerate the commercial rollout of its newly approved ophthalmic generic across the country.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=72433\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zhaoke Ophthalmology Signs Exclusive Distribution and Promotion Agreement With Pengpai Bio for Epinastine Hydrochloride Eye Drops in Mainland China\" \/>\n<meta property=\"og:description\" content=\"Zhaoke Ophthalmology (HKG: 6622) announced that it has entered into an exclusive distribution and promotion agreement with Pengpai Bio for Epinastine Hydrochloride Eye Drops, covering all sales channels in Mainland China (excluding Hong Kong, Macao, and Taiwan) \u2014 a move designed to accelerate the commercial rollout of its newly approved ophthalmic generic across the country.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=72433\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-13T04:01:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-13T04:01:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72433#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72433\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Zhaoke Ophthalmology Signs Exclusive Distribution and Promotion Agreement With Pengpai Bio for Epinastine Hydrochloride Eye Drops in Mainland China\",\"datePublished\":\"2026-08-13T04:01:20+00:00\",\"dateModified\":\"2026-08-13T04:01:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72433\"},\"wordCount\":375,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"HKG: 6622\",\"Ophthalmology\",\"Pengpai Bio\",\"Zhaoke Ophthalmology\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72433#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72433\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=72433\",\"name\":\"Zhaoke Ophthalmology Signs Exclusive Distribution and Promotion Agreement With Pengpai Bio for Epinastine Hydrochloride Eye Drops in Mainland China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-13T04:01:20+00:00\",\"dateModified\":\"2026-08-13T04:01:21+00:00\",\"description\":\"Zhaoke Ophthalmology (HKG: 6622) announced that it has entered into an exclusive distribution and promotion agreement with Pengpai Bio for Epinastine Hydrochloride Eye Drops, covering all sales channels in Mainland China (excluding Hong Kong, Macao, and Taiwan) \u2014 a move designed to accelerate the commercial rollout of its newly approved ophthalmic generic across the country.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72433#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72433\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72433#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zhaoke Ophthalmology Signs Exclusive Distribution and Promotion Agreement With Pengpai Bio for Epinastine Hydrochloride Eye Drops in Mainland China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Zhaoke Ophthalmology Signs Exclusive Distribution and Promotion Agreement With Pengpai Bio for Epinastine Hydrochloride Eye Drops in Mainland China - Insight, China&#039;s Pharmaceutical Industry","description":"Zhaoke Ophthalmology (HKG: 6622) announced that it has entered into an exclusive distribution and promotion agreement with Pengpai Bio for Epinastine Hydrochloride Eye Drops, covering all sales channels in Mainland China (excluding Hong Kong, Macao, and Taiwan) \u2014 a move designed to accelerate the commercial rollout of its newly approved ophthalmic generic across the country.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=72433","og_locale":"en_US","og_type":"article","og_title":"Zhaoke Ophthalmology Signs Exclusive Distribution and Promotion Agreement With Pengpai Bio for Epinastine Hydrochloride Eye Drops in Mainland China","og_description":"Zhaoke Ophthalmology (HKG: 6622) announced that it has entered into an exclusive distribution and promotion agreement with Pengpai Bio for Epinastine Hydrochloride Eye Drops, covering all sales channels in Mainland China (excluding Hong Kong, Macao, and Taiwan) \u2014 a move designed to accelerate the commercial rollout of its newly approved ophthalmic generic across the country.","og_url":"https:\/\/flcube.com\/?p=72433","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-13T04:01:20+00:00","article_modified_time":"2026-08-13T04:01:21+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=72433#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=72433"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Zhaoke Ophthalmology Signs Exclusive Distribution and Promotion Agreement With Pengpai Bio for Epinastine Hydrochloride Eye Drops in Mainland China","datePublished":"2026-08-13T04:01:20+00:00","dateModified":"2026-08-13T04:01:21+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=72433"},"wordCount":375,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["HKG: 6622","Ophthalmology","Pengpai Bio","Zhaoke Ophthalmology"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=72433#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=72433","url":"https:\/\/flcube.com\/?p=72433","name":"Zhaoke Ophthalmology Signs Exclusive Distribution and Promotion Agreement With Pengpai Bio for Epinastine Hydrochloride Eye Drops in Mainland China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-13T04:01:20+00:00","dateModified":"2026-08-13T04:01:21+00:00","description":"Zhaoke Ophthalmology (HKG: 6622) announced that it has entered into an exclusive distribution and promotion agreement with Pengpai Bio for Epinastine Hydrochloride Eye Drops, covering all sales channels in Mainland China (excluding Hong Kong, Macao, and Taiwan) \u2014 a move designed to accelerate the commercial rollout of its newly approved ophthalmic generic across the country.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=72433#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=72433"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=72433#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Zhaoke Ophthalmology Signs Exclusive Distribution and Promotion Agreement With Pengpai Bio for Epinastine Hydrochloride Eye Drops in Mainland China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72433","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=72433"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72433\/revisions"}],"predecessor-version":[{"id":72434,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72433\/revisions\/72434"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=72433"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=72433"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=72433"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}